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Abbreviation 
ANOVA  analysis of variance 
cAMP   cyclic adenosine monophosphate 
CCR   CC chemokine receptor 
CHO   Chinese hamster ovary 
CX3CR1  CX3C chemokine receptor 1 
DRG   dorsal root ganglion 
EC50   half maximal (50%) effective concentration 
EDTA   ethylenediaminetetraacetic acid 
EGTA   ethylene glycol tetraacetic acid 
GPCR   G protein-coupled receptor 
[35S]GTPS  guanosine 5’-O-(3-[35S]thio)triphosphate 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IBD   inflammatory bowel disease 
IC50   half maximal (50%) inhibitory concentration 
IFN   interferon 
Ig   immunoglobulin 
IL   interleukin 
LSD   least significant difference 
MCP-1   monocyte chemoattractant protein-1 
MFI   mean fluorescence intensity 
NK cell   natural killer cell 
PBS   phosphate-buffered saline 
PDE   phosphodiesterase 
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PVT   polyvinyltoluene 
QOL   quality of life 
RLU   relative light units 
SAR   structure-activity relationship 
SCID   severe combined immunodeficiency 
Th   T-helper 
TNF   tumor necrosis factor 
TRPV1   transient receptor potential vanilloid 1 
WGA   wheat germ agglutinin 
1 
 
Chapter 1. Preface 
 
     The mission of the pharmaceutical industries is to contribute to the improvement 
of welfare of people in the world by developing and supplying an excellent medicine.  
The medicines show the effect by changing the intercellular or intracellular transmission.  
Most of drug targets are proteins from the view point of molecular biology. According 
to literature that researched the drug targets in 1996, cell membrane receptors including 
GPCR (G protein-coupled receptor) constitute the largest subgroup with 45% of all 
targets, and enzymes account for 28% of all researched drug targets [1]. 
     The basis in a modern drug development process was a process that had been 
used to select the antibiotic drugs. The drug development was able to be advanced with 
a simple method due to clear drug target such as pathogen microorganism. Cimetidine, 
histamine type 2 receptor antagonist, was discovered by J. Black in 1950’s, and the 
medicine is widely used for the treatment of acid-peptic disease and heartburn. The 
basic model in the research and development process of a modern drug development 
completed this time. The process is shown in Fig. 1-1 [2]. 
     The processes from finding of hit compounds to optimization of lead compounds 
are called drug discovery as screening step of drug candidates. First of all, it is 
necessary to construct the screening system in the process. It is the first stage where the 
compound judges whether there is a possibility as a medicine. The originality of the 
screening system is a key to find the candidate compound. In a case of no information 
on compound structure to find the medicine, the compounds are screened at random and 
the hit compounds are selected based on pharmacological activity and tractability of 
compound synthesis. The group of compounds used at random is called the compound 
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library, and hit rate in the screening depends on diversity of compound scaffold not the 
number of compounds at the library. Common chemical structure in the hit compounds, 
which have pharmacological activity, indicates a series of structural aspect which is 
recognized to drug target molecule. It is a little that a perfect lead compound appears in 
a short-term screening. Medicinal chemists change the side chain of the hit compounds 
based on investigation of relationship between the compound structure and activity, and 
select the lead compounds by improving the pharmacological effect. To select the 
candidate compound with potent pharmacological activity and few side effects, the 
medicinal chemists perform compound optimization by more detail modification of the 
lead compound. In the process, originality and high technology of the medicinal 
chemists are required, and two or more evaluation systems are additionally utilized 
including in vitro assay systems and in vivo disease model systems.   
     To decide the molecule of drug target, it is necessary to decide the disease as the 
drug indication. The item considered to decide the disease is as follows: robust 
relationship between drug target and disease, trends of the diseases and patients, 
necessity on clinical site, differentiation with in existence drug, assumed sales and profit. 
According to the disease investigation, two drug discovery projects were undertaken to 
create novel anti-inflammatory drugs for the treatment of atopic dermatitis and IBD 
(inflammatory bowel disease). The drug targets were decided to PDE4 and CX3CR1 for 
atopic dermatitis and IBD, respectively. 
     To find candidate compounds in the two drug discovery programs, compound 
screening system, in vitro assay system and in vivo disease model were established 
(Table 1-1) [3 – 6]. In the project to find compound that show blockage of CX3CR1 
pathway, GPCR-focused library was utilized as screening library according to the 
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feature of the target molecule. Identification of candidate compounds, E6005 and E6130, 
was achieved by utilization of the compound evaluation system and contribution of 
medicinal chemists.  
     To investigate whether it is worth that the candidate compounds introduce clinical, 
pharmacological study of these compound was performed and described in this 
dissertation. 
 
 
  
  
Fig. 
 
1-1 Flow of drug discovery. 
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Table 1-1. In vitro and in vivo assays to find candidate compounds 
 
  
E6005 E6130
Screening
compounds Small molecule compound library (created by Eisai)
Screening
assay PDE4 enzyme assay
Fluorescent microvolume assay
(Receptor binding assay)
In vitro assay TNF- production assay Fractalkine-inducedchemotaxis assay
In vivo assay Oxazolone-inducedatopic dermatis model
CD4+CD45RbhighＴ cell-transferred 
colitis model
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Chapter 2. Mechanism elucidation of anti-pruritic effect of 
selective PDE4 inhibitor E6005 as a therapeutic agent of atopic 
dermatitis 
 
2.1. Introduction 
     Atopic dermatitis is a chronic inflammatory skin disease associated with pruritus. 
In cases of chronic atopic dermatitis lesions, pruriceptive neurons are sensitized by 
inflammatory mediators to respond more intensely and at a lower threshold to 
pruritogenic stimulation [7, 8], intensifying the itch and contributing to the chronic 
nature of the lesion [9]. Chronic pruritus is poorly managed by current treatment 
approaches such as antihistamines and topically applied steroids. The inadequacy of 
current conventional antipruritic therapy necessitates the development of new agents 
with novel mechanisms of action. 
     According to an epidemiological survey by the International Study of Asthma and 
Allergies in Childhood (ISAAC), the prevalence of atopic dermatitis is 7.3% at ages 6 to 
7 (prevalence in regional surveys ranged from 1.1% to 18.4%; 16.9% in Japan); and 
7.4% at ages 13 to 14 (prevalence in regional surveys: 0.8% to 17.7%; 10.5% in Japan). 
Prevalence tended to be high in Oceania, Northern Europe, and industrially advanced 
countries, and lower in developing countries such as Asia and Eastern Europe [10, 11]. 
The following prevalences were reported in adults in Japan and the U.S., respectively: 
adults in their 20’s: 9.8%, 18%; 30’s: 3.5% to 8.7%, 13%; 40’s: 3.1% to 4.4%, 10%; and 
50’s-60’s: 2.6%, 4% to 6% [12 – 14]. Prevalence thus tends to decrease with age. 
     Atopic dermatitis is a subtype of eczema/dermatitis, and infiltration of 
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inflammatory cells, including lymphocytes, eosinophils, and mast cells are present in 
eczema lesions [15, 16]. Leukocyte infiltration into skin lesions is caused by 
chemokines, which are produced in the epidermal keratinocyte [17], and in particular, 
the level of the Th2 chemokine, thymus and activation-regulated chemokine 
(TARC)/CCL17 is correlated with the severity of atopic dermatitis [18]. 
Antigen-presenting cells and mast cells in the skin are involved in inflammatory 
reactions by presenting antigens or releasing histamines and cytokines through the 
engagement of allergen-specific IgE antibodies to high-affinity IgE receptors. In the 
acute stage, IL-4, 5, 9, 10, and 13 are produced from Th2 cells, and in the chronic stage, 
IFN- and IL-2 are produced from Th1 cells, which aggravate the disease and cause 
chronicity. These inflammatory reactions can also be induced by environmental factors 
such as bacterial infections [19]. 
     Cyclic AMP (cAMP) is an intracellular signal molecule which modulates various 
cellular responses. Intracellular cAMP levels, which are regulated by a balance between 
production by adenylate cyclase and degradation by phosphodiesterase (PDE), modulate 
a signal transduction cascade leading to cellular response. There are several PDE 
isozymes. PDE4 is a major isozyme involved in the inflammatory reaction, which plays 
an important role in the activation of inflammatory cells including T cells and 
monocytes [20, 21]. The exaggerated response of inflammatory cells leads to various 
diseases. In atopic dermatitis, increased PDE activation in monocytes is thought to be 
involved in pathogenesis, through the induction of an abnormal inflammatory response 
[22]. Monocytes in patients have decreased levels of cAMP, due to increased PDE 
activity, which promotes the production of prostaglandin E2 and IL-10. This results in 
an increase of IL-4, but a decrease of IFN- production in T-cells and subsequent 
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activation of Th2 cells, and eventually causes the development of the disease.  
     Atopic dermatitis is accompanied by dry skin due to abnormalities in the 
physiological function of the skin, and reduced moisture from abnormal barrier function 
[23]. On the other hand, the intense itching associated with atopic dermatitis induces 
scratching, which leads to secondary inflammatory skin lesions [24]. This intense 
itching results from itch hyper-sensitivity caused by lowering of the response threshold 
of peripheral nerves to pruritogens including histamine [7, 25], the sprouting of nerve 
endings [26], and the spontaneous activity of itchy C-fibers [27 – 29]. 
     Currently, there is no drug treatment that completely cures atopic dermatitis [30, 
31]. Topical steroids are the first-line treatment for atopic inflammation, and the 
appropriate potency is selected based on both the severity and location of the rash and 
the age of the patient. Tacrolimus ointment, a calcineurin inhibitor, is indicated for use 
when topical steroids are not sufficiently effective or when adverse drug reactions are a 
concern. UV phototherapy and oral cyclosporine can be administered in the most severe 
cases. In addition, skin care with moisturizing and protective agents is recommended for 
treating abnormalities in the physiological function of the skin. There are often specific 
aggravating factors in the daily life of the patient. The identification and subsequent 
elimination of these factors, as well providing lifestyle guidance to the patient should be 
considered. On the other hand, antihistamines and anti-allergy drugs are also used to 
prevent itching and aggravation of symptoms from scratching. However, they have a 
poor effect on pruritogens other than histamine [7, 25]. These oral medications should 
be considered as an adjuvant to topical therapy. Even under the current therapeutic 
system, the disturbance of sleep due to itching is significant, which has a major impact 
not only on the patient’s QOL, but also on the QOL of the patient’s family [32]. 
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     In the pathogenesis of atopic dermatitis, an itch-scratch-inflammation cycle is 
established. As a result of interactions between itching and inflammation, skin lesions 
become aggravated and chronic. Currently, there are no effective drugs for itching, and 
a drug which is demonstrated to be effective for both itching and inflammation would 
have the potential to become a promising new therapeutic agent. Ishii et al. reported that 
the PDE4 inhibitor, E6005 showed an immediate anti-pruritic effect as well as an 
anti-inflammatory effect with suppressed cytokine expression [33] (Figs. 2-1 – 2-3, 
Table 2-1). However, the mechanism underlying the immediate anti-pruritic effect of 
E6005 remains unknown. 
     In this chapter, I describe the anti-pruritic effect of E6005 in an itch model and 
evaluate a putative mechanism of pruritus inhibition. My study demonstrated that 
E6005 suppressed pruritus by inhibiting C-fiber nerve depolarization evoked by TRPV1 
activation, through modulation of cAMP signaling. Itch is a major manifestation in a 
number of skin disorders, including atopic dermatitis. E6005 holds promise as a novel 
anti-itch therapy. 
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2.2. Materials and Methods 
2.2.1. Test compound and reagents 
     E6005 [6], roflumilast and JNJ17203212 were synthesized in-house at Eisai Co., 
Ltd.  Chemical structures of E6005 and roflumilast are shown in Figs. 2-4 and 2-5, 
respectively. Vaseline-based E6005 ointment was prepared in-house at Eisai Co., Ltd. 
Oxazolone, forskolin, betamethasone, naltrexone hydrochloride, capsaicin, collagenase 
type IV, amitriptyline, bupivacaine, and lidocaine were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Terfenadine was purchased from Kanto Chemicals Co., Inc. 
(Tokyo, Japan). FK506 (tacrolimus) was purchased from Wako Pure Chemical 
Industries Ltd. (Osaka, Japan). Rat -NGF was purchased from R&D Systems Inc. 
(Minneapolis, MN, USA). 
 
2.2.2. Animals 
     Male HR-1 mice (5 weeks old) and male Wistar rats (5 weeks old) were 
purchased from Hoshino Experimental Animal Supply (Saitama, Japan) and Charles 
River Laboratories Japan, Inc. (Kanagawa, Japan), respectively. All animals were kept 
in a pathogen-free animal facility with temperature maintained at 2026C, humidity 
4070%, and a 12-h day/night cycle, with access to food and water ad libitum. All 
procedures were performed at the animal facility accredited by the Center for 
Accreditation of Laboratory Animal Care and Use, Japan Health Sciences Foundation.  
     All protocols were approved by the Institutional Animal Care and Use Committee 
and carried out according to Eisai Animal Experimentation Regulations. 
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2.2.3. Isolation of dorsal root ganglion (DRG) neurons 
     Primary dorsal root ganglion (DRG) neurons were isolated as previously 
described with slight modifications [34]. Briefly, isolated DRG from adult Wister rats 
were collected in cold Hank’s balanced salt solution (HBSS), centrifuged, and then 
re-suspended in F-12 nutrient mixture containing collagenase (2 mg/mL) and fetal calf 
serum (FCS, 10%). After 90 min of incubation at 37C with agitation, the cells were 
spun down and treated with Trypsin-EDTA solution for 15 min at 37C. The suspension 
of neurons was washed and suspended in Dulbecco’s modification of Eagle’s medium 
(DMEM) containing 10% FCS. Cultures were maintained for 2-4 days in a humidified 
atmosphere (37C, 5%CO2). 
 
2.2.4. Electrophysiological recordings 
     Small-sized DRG neurons (diameter, <30 m), which have been shown to exhibit 
high capsaicin sensitivity [35, 36], were selected for whole-cell patch clamp recording 
at room temperature (20-22C) by using an Axopatch 1D amplifier (Axon Instruments, 
Union City, CA, USA). The micropipettes used had resistances of 2-6 M. The 
standard pipette solution contained 4 mM ATP, 130 mM KCl, 2 mM MgCl26H2O, 5 
mM EGTA, 0.5 mM CaCl2, and 10 mM HEPES, with pH adjusted to 7.2 by using 
NaOH. The standard external solution contained 130 mM NaCl, 5 mM KCl, 2 mM 
MgCl26H2O, 2 mM CaCl2, and 10 mM HEPES. The low-pass filter was set at 5 kHz. 
The cells were superfused with combinations of capsaicin with vehicle, E6005 (0.1 μM 
and 1 μM), roflumilast, betamethasone, or tacrolimus. All data acquisition and analysis 
were performed using pClamp 8.02 software (Axon Instruments, Sunnyvale, CA, USA). 
The capsaicin-evoked membrane depolarization (mV) was calculated as the difference 
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between the membrane potential measured before and after the addition of capsaicin. 
 
2.2.5. Nav1.2 current assay 
     hNav1.2-CHO cell line has been established in Eisai Tsukuba Labs. The cells 
were grown in DMEM+GlutaMAXTM –I medium (10569, Gibco, Waltham, MA, USA) 
containing 5% FBS and Antibiotic-Antimycotic (15240, Gibco, Waltham, MA, USA). 
Two or 3 days before the automated patch clamp experiments using IonWorks-Quattro 
(Molecular Devices Corporations, San Jose, CA, USA), 1 or 0.5 x 106 cells was seeded 
into F225 culture flasks. After rinse by D-PBS(-) (045-29795, Wako, Osaka, Japan) and 
treatment by 0.05% trypsin-EGTA (25300, Gibco, Waltham, MA, USA), cells were 
collected and suspended into the external buffer at the density of 5.0 x 106 cells/mL. For 
the patch clamp experiments, the external buffer contained 138 mM NaCl, 2.7 mM KCl, 
0.9 mM CaCl2, 0.5 mM MgCl2, 1.5 mM KH2PO4, and 8.1 mM Na2HPO4 and the 
internal buffer contained 100 mM K-gluconate, 40 mM KCl, 3.2 mM MgCl2, 5 mM 
EGTA and 5 mM HEPES. Nav1.2 current was evoked by the application of train of 30 
pulses to 0 mV from a holding potential of -70 mV at 20 Hz. 
 
2.2.6. Oxazolone-induced pruritus model in HR-1 mice 
     Oxazolone-induced dermatitis was developed in HR-1 mice according to the 
method described in a previous report [38] with some modifications. Briefly, HR-1 mice 
were sensitized by painting 100 L of 0.5% oxazolone dissolved in acetone/ethanol 
solution (1:1) onto the skin of the abdomen. Scratching was evoked by painting 10 L 
of 1-1.5% oxazolone solution onto ear skin twice a week, starting from 6 days after 
sensitization. Scratching behavior was quantified using the MicroAct system 
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(Neuroscience, Inc., Tokyo, Japan). The instances of scratching behavior were counted 
for 90 min. Naltrexone hydrochloride was dissolved in saline and was subcutaneously 
administered 15 minutes before the 4th oxazolone challenge. Terfenadine was dissolved 
in saline and was orally administered 1 h before the 4th oxazolone challenge. Forskolin 
was dissolved in acetone/ethanol solution (1:1) and was topically administered 1 h 
before the 4th oxazolone challenge. JNJ17203212 was dissolved in polyethylene glycol 
400 and was orally administered 1 h before the 4th oxazolone challenge. Vaseline-based 
E6005 ointment was administered topically 4-5 h before the 4th-6th challenge. 
 
2.2.7. Statistical analysis 
     In all studies except electrophysiological study, the Student’s t-test was used to 
analyze differences between two groups, and the Dunnett test was used for multiple 
comparisons among treatment groups. P values <0.05 were considered statistically 
significant. 
     In the electrophysiological study, data were analyzed using unpaired t-tests and 
one-way ANOVA followed by Dunnett’s multiple comparison test by using the software 
package SAS ver. 6.12 (SAS Institute Japan, Ltd., Tokyo, Japan). A value of p < 0.05 
(two-sided) was considered statistically significant. 
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2.3. Results 
2.3.1. Effect of E6005 on capsaicin-evoked depolarization of dorsal root ganglion 
(DRG) neurons  
     The effect of E6005 on depolarization evoked by capsaicin, a TRPV1 agonist, 
was examined in the primary small-sized DRG neurons, which have been reported to be 
relevant to itch [35, 36]. Under current-clamp condition, 1 M capsaicin elicited a 
typical change in membrane potential and action potential firing (Fig. 2-6a), which was 
attenuated by E6005 in a concentration-dependent manner (Fig. 2-6bc). Roflumilast, a 
structurally distinct PDE4 inhibitor, also decreased the capsaicin-evoked membrane 
potential change (Fig. 2-6c). Anti-inflammatory agents tacrolimus and steroid 
betamethasone did not significantly alter capsaicin-induced changes in membrane 
potential in this experimental setting (action potential firing rate of tacromilus: 2/4, 
betamethasone: 3/5). In contrast, forskolin, an agent that activates the cAMP signaling 
pathway, reduced the magnitude of depolarization (Fig. 2-6d). 
 
2.3.2. Effects of E6005, naltrexone, terfenadine, forskolin and JNJ17203212 on 
oxazolone-induced scratching behavior in HR-1 mice 
     Oxazolone-induced dermatitis is characterized by severe mononuclear cell 
recruitment. This characteristic inflammatory skin damage means that 
oxazolone-dermatitis is a useful in vivo tool for pathogenic studies to select potential 
therapeutics for the treatment of inflammatory responses associated with the skin. A 
mouse model of chronic scratching was established by application of the chemical 
irritant oxazolone and used to assess the anti-pruritic effect of E6005. 
Oxazolone-sensitized mice were repeatedly challenged on the ear with re-application of 
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oxazolone to establish intermittent scratching responses upon irritations. Oxazolone 
challenge initially elicited a weak response with approximately 200 instances of 
scratching. The number of scratching instances increased with repeated application of 
oxazolone, reaching a plateau after the 3rd challenge (Fig. 2-7). The scratching behavior, 
as assessed at the 4th application of oxazolone, was resistant to histamine H1-receptor 
antagonist terfenadine, but sensitive to an opioid receptor antagonist naltrexone (Fig. 
2-8ab), reflecting the observations in atopic dermatitis patients [39]. E6005 ointment 
(0.01% and 0.03%, w/v) caused an immediate and significant reduction of scratching 
response in a dose-dependent manner at day 15. Furthermore, application of E6005 
ointment at 3 or 4-day intervals attenuated the scratching at each oxazolone-challenge in 
a dose-dependent manner (Fig. 2-9). In order to evaluate the involvement of cAMP 
elevation on scratching behavior, the effect of adenylyl cyclase-activator forskolin was 
assessed. Forskolin application significantly decreased oxazolone-elicited scratching 
behavior with immediate effect, as assessed 15 days after sensitization (Fig. 2-10a). 
     To study the involvement of transient receptor potential vanilloid 1 (TRPV1) in 
the chronic itch model, the effect of TRPV1 antagonist JNJ17203212 was examined. 
Oral administration of 30 mg/kg JNJ17203212 significantly reduced oxazolone-elicited 
scratching (Fig. 2-10b). 
 
2.3.3. Effect of E6005, amitriptyline, bupivacaine, and lidocaine on Na+ current 
recorded in hNav1.2-CHO cells 
     Topical application of E6005 immediately inhibits itching behaviour as well as 
itch-related cutaneous nerve firing in a mouse model. Local anaesthetics such as 
Na+-channel blockers have been used clinically for relief of pruritus. To verify whether 
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this effect is due to a local anaesthetic activity, effect of E6005 on Na+ current recorded 
in hNav1.2-CHO cells was investigated. The Na+-channel blockers amitriptyline, 
bupivacaine, and lidocaine inhibited Nav1.2 current in a concentration-dependent 
manner, with half-maximal inhibitory concentration (IC50) values (µM) of 1.3, 3.3, and 
86.3, respectively. E6005 did not show any inhibitory activity for Nav1.2 current at ≤20 
µM (Fig. 2-11). In this experiment, the maximal attainable concentration of E6005 was 
20 µM owing to its limited solubility. 
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2.4. Discussion 
     In chronic pruritic skin, C-fibers are rendered more responsive to pruritogenic 
stimulations by inflammatory mediators, resulting in intense and persistent itch response 
[7, 8]. In my chronic itch model, established by repeated stimulation with a chemical 
irritant, skin lesions showed typical symptoms of chronic pruritic skin, such as 
reddening and thickening [33]. Scratching behavior was observed to increase with the 
progression of inflammation, as seen in patients, reaching a reproducible scratch 
response to the skin irritant following repeated applications. Topically applied E6005 
and cAMP-elevating agent forskolin suppressed the scratching behavior with immediate 
effect in this model, indicating that E6005 possessed therapeutic potential for 
management of chronic pruritus. Interestingly, the observed anti-pruritic effects 
preceded the improvement of inflammatory symptoms. Additionally, the inhibition of 
scratching by topical forskolin administration suggests that cAMP signaling plays a 
suppressive role in the process of itch generation, confirming previous findings by other 
laboratories [40]. 
     TRPV1 played a role in the generation of itch in my chronic scratching model. 
Recent advances in neurophysiology of pruritus revealed that C-fibers can be 
categorized as two distinct nerve fiber types by size, with the smaller TRPV1-positive 
population playing a major role in the generation of itch [36, 41 – 43]. The population 
of smaller DRG nerve fibers was selected for the electrophysiological investigation. The 
DRG neurons studied showed rapid depolarization in response to the TRPV1 activator 
capsaicin, with increased membrane potential firings. Attenuation of capsaicin-induced 
membrane depolarization by two structurally different PDE4 inhibitors suggests that 
inhibition of PDE4 enzymes modulates C-fiber function. Additionally, cAMP elevator 
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forskolin diminished the capsaicin-induced depolarization, suggesting that the inhibition 
of membrane depolarization by E6005 may be mediated by alterations of cAMP 
signaling. These findings demonstrated that PDE4 inhibition could suppress DRG 
function by increasing intracellular cAMP levels, which contributes to the immediate 
anti-scratching mechanism. In contrast to the effects of E6005 and roflumilast, 
anti-inflammatory drugs betamethasone and tacrolimus did not significantly suppress 
nerve activation [33]. Since steroid administration did not inhibit the scratching 
behavior [33], the ability of tested compounds to suppress the TRPV1-mediated 
depolarization of DRG nerve fibers seemed to be reflected in their immediate 
anti-scratching effect in vivo. Tacrolimus is, however, reported to inhibit DRG 
activation by a longer pretreatment than my study [44]. The lack of the effect in my 
study may be due to the inadequate pre-incubation time. E6005 directly affected DRG 
neuron. But, the mode of action seems to unlike tacrolimus because E6005 exerted the 
suppressive effect without stimulating DRG. This was also confirmed by measuring 
C-fiber activity in animals with atopic dermatitis [45] and absence of burning in patients 
with atopic dermatitis [46]. Finally, my findings allow to rule out the possibility that the 
observed inhibition of scratching behavior of E6005 is due to local anesthetic activity 
because it did not inhibit the sodium channel responsible for local anesthesia (Fig. 2-8). 
The inhibitory effect of cAMP on depolarization was intriguing but was in contrast to 
that on pain, upon which it augments the sensitivity and magnitude. Han et al. reported 
that TRPV1-positive itch-specific DRG neurons that express the Mas-related G 
protein-coupled receptor (Mrgpr) generate itch but not pain upon capsaicin stimulation 
[43]. In addition, distinct mechanisms for intra-cellular signaling between itch and pain 
generation have been suggested [46]. In the present study, forskolin suppressed 
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depolarization, instead of augmenting it, and cutaneous cAMP elevation has been shown 
to decrease itching in a mouse model of chronic itch [45]. Therefore, a distinct 
cAMP-driven inhibitory signal might be present in itch-related DRG neurons. Further 
experiments to study the modification of intra-cellular molecules by cAMP as well as 
Mrgpr expression in the preparation of DRG neurons are required to confirm the effect 
of E6005 on DRG neurons. 
     As summary of this chapter, I show that E6005, which was identified via 
screening of Eisai’s small molecule compound libraries and chemical optimization 
based on structure activity relationship approach, may provide a new approach to 
manage skin inflammation and pruritus in the treatment of atopic dermatitis. As a next 
step, to study whether the evaluation system of drug discovery is also suitable for other 
drug discovery program, screening system of the compound libraries was established to 
develop an anti-inflammatory drug through inhibition of CX3CR1 pathway for 
treatment of IBD. I show pre-clinical efficacy of E6130, which was identified from the 
screening and chemical optimization, as the drug of IBD in the next chapter. 
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Table 2-1. In vitro inhibitory effects of E6005 on cytokine release in lymphocyte and 
monocyte derived from human peripheral blood 
 
Data given as mean IC50 values (nM) calculated from concentration-inhibition curves 
from three different experiments; 95% confidence intervals are shown in parentheses. 
aAnti-CD3/CD28 antibody-stimulated. 
bPhytohemagglutinins-P-stimulated. 
cLipopolysaccharide-stimulated. 
IFN-γ = interferon-γ, IL-2, -4, -12 = interleukin 2, -4, -12, TNF-α = tumor necrosis 
factor-α. 
  
IL-2a IL-4a IFN-b TNF-b IL-12c TNF-c
3.1
(2.0 - 4.9)
2.7
(0.90 - 8.3)
0.87
(0.015 - 52)
0.78
(0.38 - 1.6)
0.49
(0.21 - 1.2)
0.79
(0.085 - 7.4)
Lymphocyte Monocyte
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Fig. 2-1 Assumed mode of action of E6005. 
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Fig. 2-2 Theraputic effect of topically applied E6005 on oxazolone-induced dermatitis 
score in NC/Nga mice. 
15 µL of 0.003% E6005 ointment (solid squares), 0.01% E6005 ointment (solid 
triangles), 0.03% E6005 ointment (solid inverted triangles), or Vaseline based-vehicle 
ointment (solid circles) was administrated once a day from day 12 to day 18 onto the 
ears of NC/Nga mice that were sensitized and challenged with oxazolone. Skin lesion 
was scored according to the following symptoms: erythema/hemorrhage, excoriation, 
and oozing/crusting. Results are expressed as the mean  S.E.M. (n = 19 or 20). * P  
0.05 versus the vehicle-treated group. 
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Fig. 2-3 Effect of E6005 on oxazolone-induced scratching behavior in NC/Nga mice. 
E6005 ointment (from 0.003 to 0.03%) or Vaseline-based vehicle ointment was applied 
on the ear of NC/Nga mice that were sensitized and challenged with oxazolone. 
Scratching behavior was induced 4–5 h after the administration of each compound and 
then evaluated for 120 min. Results are expressed as the mean  S.E.M. (n = 24). * P  
0.05 versus the vehicle-treated and oxazolone-challenged group. 
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Fig. 2-4 Chemical structure of E6005. 
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Fig. 2-5 Chemical structure of roflumilast. 
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Fig. 2-7 Scratching behaviour in sensitized HR-1 mice induced by repeated application 
of oxazolone. 
Starting 6 days following oxazolone-sensitization, HR-1 mice were administered 
acetone (vehicle; open bars) or oxazolone solution (solid bars) twice week by topical 
application to ear skin. The incidences of scratching were counted for 90 min, as 
described in the Materials and Methods. Results are expressed as mean ± S.E.M. of 8 
mice. *p < 0.05 vs the acetone-challenged control group. 
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Fig. 2-8 Effects of -opioid receptor antagonist naltrexone and histamine H1 receptor 
antagonist terfenadine on oxazolone-induced scratching behaviour in HR-1 mice. 
Sensitized mice were repeatedly challenged with oxazolone, as described in Materials 
and Methods. (a) Naltrexone was injected subcutaneously before the 4th oxazolone 
challenge. (b) Terfenadine was orally administered before the 4th oxazolone challenge. 
Scratching behavior was induced 15 or 60 min after naltrexone or terfenadine 
administration, respectively. Incidences of scratching were counted for 90 min and the 
results expressed as mean ± S.E.M. of 8 mice. *p < 0.05 vs the vehicle-treated group. 
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Fig. 2-9 Effect of E6005 on oxazolone-induced scratching behavior in HR-1 mice. 
Sensitized HR-1 mice were repeatedly challenged on the ear with oxazolone twice a 
week as described in Fig. 2-5. (a) Vehicle ointment (solid diamonds), 0.01% (solid 
triangles), or 0.03% (solid circles) E6005 ointment was topically administrated before 
each oxazolone challenge performed 15, 19, and 23 days following sensitization. 
Vehicle ointment (open diamonds) was topically administrated before each acetone 
challenge performed 15, 19, and 23 days following sensitization. Scratching behavior 
was induced 4-5 h after the administration of each ointment and incidences of 
scratching were counted for 90 min. Results are expressed as mean ± S.E.M. of 32 mice. 
*p < 0.05 vs the vehicle-treated group on day 15.  
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Fig. 2-10 Effect of E6005 on oxazolone-induced scratching behavior in HR-1 mice. 
Sensitized HR-1 mice were repeatedly challenged on the ear with oxazolone twice a 
week as described in Fig. 2-5. (a) Forskolin solution or vehicle (50% acetone/50% 
ethanol) was topically administrated before the 4th oxazolone challenge. Scratching 
behavior was induced 1 hour after the topical application, and counted for 90 min. 
Results are expressed as mean ± S.E.M. of 12 mice. *p < 0.05 vs the vehicle-treated 
group. (b) Sensitized mice were repeatedly challenged by application of oxazolone to 
the ear skin twice a week. TRPV1 antagonist JNJ17203212 (30 mg/kg) was orally 
administrated before the 4th oxazolone challenge. Scratching behavior was induced 1 
hour after the administration and incidences of scratching counted for 90 min. Results 
are expressed as mean ± S.E.M. of 8 mice. *p < 0.05 vs the vehicle-treated group. 
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Fig. 2-11 Effects of E6005, amitriptyline, bupivacaine and lidocaine on Na current 
recorded for the hNav1.2-CHO cells. 
Concentration-response curves obtained by train of 30 pulses in the presence of E6005 
(solid circles), amitriptyline (solid squares), bupivacaine (solid triangles), or lidocaine 
(solid inverted triangles) were described. Mean ± S.E.M. 
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Chapter 3. Pharmacological assessment of CX3CR1 modulator 
E6130 as a therapeutic agent of IBD   
 
3.1. Introduction 
     Inflammatory bowel disease is a group of idiopathic, chronic intestinal 
inflammatory diseases that primarily includes two distinct conditions: Crohn’s disease 
and ulcerative colitis, which are both the result of inappropriate immune responses to 
antigens produced by commensal microorganisms. Although the signs of Crohn’s 
disease and ulcerative colitis manifest primarily in the gastrointestinal tract, these 
diseases affect the entire human body [47]. Therapeutic treatments that inhibit cytokines 
are currently in widespread clinical use; however, the serious adverse events and lack of 
long-term efficacy of these treatments remain serious concerns. 
     Infiltration of leukocytes from the peripheral circulation into tissues such as the 
gut mucosa is an important aspect of immune surveillance. To enter the mucosal tissue 
from the blood, leukocytes must cross the endothelial barrier. They do this by 
interacting with cytokine- or other pro-inflammatory stimuli-activated endothelial cells 
via either leukocyte cell-surface chemokine receptors (and their respective endothelial 
and mucosal ligands) or via integrins and immunoglobulin superfamily cellular 
adhesion molecules [48, 49]. 
     Chemokines and their receptors are also important means of orchestrating 
tissue-specific and cell type–selective leukocyte trafficking [50]. For example, 
fractalkine (also known as CX3C motif ligand 1: CX3CL1) is a chemokine prominently 
expressed by epithelial and endothelial cells that functions as both an adhesion molecule 
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and a chemotactic factor (Fig. 3-1) [51, 52]. Fractalkine binds to its sole receptor, CX3C 
chemokine receptor 1 (CX3CR1), which is expressed on the surfaces of monocytes, 
macrophages, dendritic cells, microglia, natural killer (NK) cells, and cytotoxic effector 
T-cells that contribute to the development of chronic inflammation [53, 54]. Apart from 
a role in post-ischemic brain injury, mice deficient in either fractalkine or CX3CR1, 
bred in a sterile environment, were phenotypically indistinguishable from wild type 
mice. In patients with inflammatory bowel disease, the expression of fractalkine by 
intestinal epithelial cells and microvascular cells and of CX3CR1 by peripheral blood 
T-cells increases with the level of disease activity. Thus, the fractalkine/CX3CR1 axis 
appears to be directly involved in the pathogenesis of inflammatory bowel disease [55 – 
57]. 
     In this chapter, I summarize in vitro and in vivo pharmacological profile of a 
novel CX3CR1 modulator E6130, which was identified from Eisai’s small molecule 
compound libraries. I found that E6130 inhibited fractalkine-induced chemotaxis and 
induced down regulation of CX3CR1 on the cell surface in NK cells from human 
peripheral blood. E6130 also prevented the trafficking of CX3CR1-expressing 
leukocytes into colonic tissue in a murine CD4+CD45RBhigh T cell–transfer colitis 
model, and it ameliorated other inflammatory bowel disease–related parameters in both 
the murine CD4+CD45RBhigh T-cell-transfer colitis model and a murine 
oxazolone-induced colitis model. Together, these results suggest that E6130 is a 
promising agent for treating IBD. 
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3.2. Materials and Methods 
3.2.1. Test compound and reagents 
     E6130 was synthesized by Eisai Co., Ltd. at its plant located in Kashima, Japan 
[6]. The chemical structure of E6130 is shown in Fig. 3-2. Oxazolone was purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Recombinant human fractalkine was 
purchased from R&D Systems (Minneapolis, MN, USA). 
 
3.2.2. Animals 
     BALB/c mice (female, 7–10 weeks old) were obtained from Charles River 
Laboratories Japan, Inc. (Tokyo, Japan). SCID mice (female, 6 weeks old) were 
obtained from CLEA Japan, Inc. (Tokyo, Japan). The mice were group-housed under 
controlled conditions (temperature, 22 ± 3 °C; humidity, 55% ± 5%; 12-h light/dark 
cycle) with ad libitum access to water and standard pelleted food. 
     All animal experiments were approved by the Committee for the Welfare of 
Laboratory Animals, Eisai Co. Ltd. 
 
3.2.3. CX3CR1 down-regulation assay 
     Assay medium (RPMI 1640 medium containing 10% fetal bovine serum) (80 
L/well) and E6130 (10 L/well) were added to each well of a 96-well culture plate. 
Written informed consent was obtained from each subject before blood draw. Human 
peripheral blood was drawn from the forearm vein of three healthy male volunteers and 
an aliquot (10 L) was added to each well. After incubation for 30 min at 37 °C under 
an atmosphere of 5% CO2, the human peripheral blood cells were washed twice with 
Flow cytometry (FCM) buffer (phosphate-buffered saline [PBS] containing 1% fetal 
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bovine serum, 1 mM EDTA, 0.1% bovine serum albumin). The cells were incubated 
with FcR Blocking Reagent (Miltenyi Biotec, Germany) for 10 min on ice to block Fc 
receptor and then stained for CD56 (NK cell surface marker) and CX3CR1 by 
incubation with allophycocyanin-conjugated anti-CD56 monoclonal antibody (Miltenyi 
Biotec, Germany) and phycoerythrin-conjugated anti-CX3CR1 monoclonal antibody 
(BioLegend, CA, USA), respectively, for 30 min on ice. The cells were then washed 
once and resuspended in FCM buffer. After incubation for 10 min on ice with 7-amino 
actinomycin D (Sigma-Aldrich, MO, USA) to discriminate dead cells, the fluorescence 
intensity of the stained cells was determined by using a FACSCanto cell analyzer 
(Becton Dickinson, NJ, USA). Loss of CX3CR1 staining on the cell surface was 
assumed to represent the induction of down-regulation of CX3CR1 on the cell surface. 
The mean fluorescence intensity (MFI) of the CX3CR1+ cell population among the total 
NK cell population was also determined by using a FACSCanto cell analyzer. The 
percentage MFI of the control was determined by using the following formula: 
% MFI of control = (MFItest well – MFIbackground well) / (MFIcontrol well – MFIbackground 
well) × 100, 
where “test well” refers to wells containing E6130 and staining antibodies, “control well” 
refers to wells containing staining antibodies only, and “background well” refers to 
wells containing neither the staining antibodies nor E6130. 
 
3.2.4. Isolation of NK cells from human peripheral blood 
     An aliquot (25 mL) of human peripheral blood was added to a plastic 
centrifugation tube containing 100 units of heparin sodium (Ajinomoto, Japan). An 
aliquot (8 mL) of physiological saline containing 6% dextran (Nacalai Tesque, Japan) 
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was added to the tube and the mixture was allowed to stand at room temperature for 30 
min to allow sedimentation of the erythrocytes. The supernatant was transferred to 
another plastic centrifugation tube, mixed with an equivalent volume of PBS, and then 
centrifuged at 1,800 rpm for 7 min at room temperature. The resultant hemocyte 
fraction was suspended in 4 mL PBS and the suspension was superposed on 4 mL 
Ficoll-Paque Plus (GE Healthcare Life Sciences, Japan). After centrifugation of the 
suspension at 2,200 rpm for 30 min at room temperature, the cells in the intermediate 
layer (peripheral blood mononuclear cells) were collected, suspended in PBS, and 
centrifuged at 1,800 rpm for 7 min. The supernatant was removed and the precipitate 
was suspended in PBS containing 5 mM EDTA and 0.5% bovine serum albumin. NK 
cells were purified from the peripheral blood mononuclear cell population by means of 
negative selection using an NK cell isolation kit (Miltenyi Biotec, Germany) and a 
MACS LS column (Miltenyi Biotec, Germany). Cells passing through the column were 
considered NK cells and were collected, washed, and suspended in chemotaxis buffer 
(RPMI 1640 medium containing 10% fetal bovine serum, 50 M 2-mercaptoethanol, 
and 10 mM HEPES). 
 
3.2.5. Chemotaxis assay 
     Human fractalkine solution (solved in chemotaxis buffer, 60 L/well) and 
chemotaxis buffer (480 L/well) were added to the lower wells of a 24-well chemotaxis 
assay chamber (Boyden chamber, pore size: 5.0 m) with final concentration of 0.2 nM. 
E6130 solution (60 L/well) was also added to the lower wells. A mixture of NK cell 
suspension and E6130 was added to the upper wells and the chambers were incubated 
for 2 h at 37°C under an atmosphere of 5% CO2. After incubation, the content of the 
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upper wells was discarded and the assay chambers were centrifuged at 1,800 rpm for 5 
min. The supernatant was removed and a CellTiter-Glo reagent (Promega Corporation, 
Japan) was added to the precipitate. Chemiluminescence intensity was measured by 
using a Wallac 1420 ARVOsx multi-label counter (PerkinElmer Japan). The number of 
cells in each well was calculated by using a standard curve fitting the regression line for 
cell number. The percentage of cells exhibiting chemotaxis was determined by using the 
following formula: 
% of control = (cell numbertest well – cell numberblank well) / (cell numbercontrol well – 
cell numberblank well)  100, 
where “test well” refers to wells containing fractalkine and E6130, “blank well” refers 
to wells containing neither fractalkine nor E6130, and “control well” refers to wells 
containing fractalkine only. 
 
3.2.6. GTPS binding assay 
     Scintillation Proximity Assay (SPA) [35S]GTPS experiments were conducted 
using CHO-K1 membranes stably expressing human chemokine receptors incubated in 
assay buffer (20 mM HEPES [pH 7.4], 100 mM NaCl, 10 g/mL saponin, 1 mM 
MgCl2). In the agonistic activity assay, E6130 or reference ligand, assay buffer, 
CHO-K1 membrane - GDP mix, [35S]GTPγS and WGA-PVT beads (Perkin Elmer, MA, 
USA) mix were successively added to the wells of an OptiPlate (Perkin Elmer, MA, 
USA). In the antagonistic activity assay, E6130 or reference ligand and CHO-K1 
membrane-GDP mix were successively added to the wells of an OptiPlate and the plates 
were incubated for 15 min at room temperature. A reference agonist at its historical 
EC80 was then added, followed by the addition of [35S]GTPγS and WGA-PVT beads. 
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     In both assays, the plates were covered with a top seal, shaken on an orbital 
shaker for 2 min, and then incubated for 1 h at room temperature. The plates were then 
centrifuged for 10 min at 2,000 rpm and incubated at room temperature for 1 h. Each 
well was counted for 1 min by using a PerkinElmer TopCount reader (Perkin Elmer, 
MA, USA). 
 
3.2.7. PathHunter -arrestin recruitment assay 
     PathHunter is a trademark of DiscoveRx [58, 59]. PathHunter cell lines were 
expanded from freezer stocks in T25 flasks according to standard procedures and 
maintained in selective growth media before assay. Once it was established that the cells 
were healthy and growing normally, the cells were passaged from the flasks by using 
cell dissociation reagent and seeded into white-walled, clear-bottomed, 384-well 
microplates. Cells were seeded at a density of 5,000/well in a total volume of 20 L and 
were allowed to adhere and recover overnight before the addition of E6130. 
     In the agonistic activity assay, intermediate dilutions of E6130 stock solutions 
were generated such that 5 L of E6130 could be added to each well to produce a final 
concentration of DMSO of 1% of the total volume. The cells were incubated in the 
presence of E6130 at 37°C for 90 min. 
     In the antagonistic activity assay, agonist dose curves were constructed and used 
to determine EC80 values. Cells were pre-incubated with antagonist; this was followed 
by agonist challenge, as follows: 5 L of E6130 was added to the cells and the plates 
were incubated at 37°C for 30 min. Then, 5 L of agonist at its EC80 was added to the 
cells and the plates were incubated at 37°C for 90 min. 
     The assay signal was generated through the addition of 12.5 or 15 L (50%, v/v) 
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of PathHunter Detection reagent cocktail for the agonistic and antagonistic activity 
assays, respectively, followed by incubation for 1 h at room temperature. The 
microplates were then read with a ParkinElmer EnVision multilabel plate reader (Perkin 
Elmer, MA, USA). 
     Dose curves in the presence of E6130 were plotted by using GraphPad Prism 
(GraphPad Software, CA, USA). In the agonistic activity assay, percentage activity was 
calculated by using relative light units (RLU) and the following formula: 
% Activity = 100% × (mean RLUtest sample − mean RLUvehicle control) / (mean MAX 
RLUcontrol ligand − mean RLUvehicle control). In the antagonistic activity assay, 
percentage inhibition was calculated by using the following formula: % Inhibition = 
100% × (1 – [mean RLUtest sample − mean RLUvehicle control] / mean RLUEC80 control − 
mean RLUvehicle control). 
 
3.2.8. CD4+CD45RBhigh T-cell preparation and T-cell-transfer colitis model 
     CD4+CD45RBhigh T cells were isolated from BALB/c splenocytes. BALB/c mice 
were euthanized by means of cervical dislocation and their spleens were removed. The 
spleens were passed through a cell strainer (BD Biosciences, NJ, USA) and a single-cell 
suspension of splenocytes was prepared. After hemolysis, the CD4+ T-cell population 
was purified from the splenocytes by means of negative selection by using a mouse 
CD4+ T-cell Isolation Kit II (Miltenyi Biotec, Germany) and a MACS LS column. For 
the preparation of CD4+CD45RBhigh T cells, the isolated total CD4+ T cells were labeled 
with phycoerythrin-conjugated mouse anti-CD4 monoclonal antibody (eBioscience, CA, 
USA) and fluorescein isothiocyanate-conjugated mouse anti-CD45RB monoclonal 
antibody (eBioscience, CA, USA), and two-color cell sorting was performed by using a 
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FACSAria cell sorter (Becton Dickinson, NJ, USA). The sorted CD4+CD45RBhigh T 
cells were suspended in PBS and intravenously transferred into SCID mice. After 2 
weeks, E6130 or vehicle [0.5% methyl cellulose (0.5% MC)] was orally administered 
once daily to the SCID mice from day 14 to day 27. Stool consistency and body weight 
of all mice were recorded on days 14, 16, 18, 20, 22, 24, 26, and 28. On Day 28, the 
mice were euthanized, their colons were removed, and the weight and length of each 
colon was recorded. Stool consistency was scored as follows: (0) Normal, (1) Soft stool 
(well-formed pellets), (2) Soft stool (very soft but formed pellets), (3) Loose stool 
(pasty stool), and (4) Diarrhea (liquid stool that sticks to the anus). Relative body 
weight was calculated by using the following formula: 
Relative body weight (%) = body weight (g) on day of measurement / body weight 
(g) on Day 14 × 100. 
     Next, the colons were washed with PBS and then incubated for 30 min at 37°C in 
PBS containing 1 mM dithiothreitol, 1 mM EDTA, and 1% fetal calf serum to remove 
epithelial cells. The remaining tissue was washed with PBS, cut into 1- to 2-mm 
sections, and incubated for 2.5 h at 37°C in RPMI 1640 containing 0.5 mg/mL 
collagenase A, 1 g/mL DNase, and 5% fetal calf serum. After incubation, the 
suspension was passed through a cell strainer and the resultant cell suspension was 
centrifuged at 700  g for 7 min at room temperature. The resultant enterocyte 
precipitate was suspended in 4 mL of PBS and the suspension was superposed on 
Percoll (GE Healthcare Life Sciences, IL, USA). After centrifugation at 700  g for 20 
min at room temperature, the cells in the intermediate layer were collected, suspended 
in PBS, and centrifuged at 700  g for 7 min at 4°C. The supernatant was removed and 
the precipitate was suspended in FACS buffer (PBS containing 1 mM EDTA, 0.1% 
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bovine serum albumin, and 1% fetal calf serum). CX3CR1+ cells were labeled with 
phycoerythrin-conjugated goat anti-CX3CR1 polyclonal antibody (R&D Systems, MN, 
USA) and the proportion of CX3CR1+ cells was determined with a FACSCanto cell 
analyzer (Becton Dickinson, NJ, USA). 
 
3.2.9. Pharmacokinetics and histological analysis in T-cell-transfer colitis model 
     For pharmacokinetic study, the sorted CD4+CD45RBhigh T cells, as described 
above, were suspended in PBS and intravenously transferred into SCID mice. After 2 
weeks, E6130 or vehicle was orally administered once daily to the SCID mice from Day 
15 to Day 30. Blood samples were withdrawn at 30 min, 2 and 6 h after administration 
of E6130 on Day 29. After centrifugation of mouse blood, concentrations were 
quantitatively determined by a mass spectrometer equipped with a high performance 
liquid chromatography (HPLC) system. 
     For histological analysis, the colon was collected from mice on Day 30, fixed in 
10% neutral buffered formalin, embedded in paraffin, and processed for microscopic 
examination of hematoxylin and eosin (H&E) stained sections. 
 
3.2.10. Oxazolone-induced colitis model 
     BALB/c mice were sensitized with oxazolone on Day 0 by painting 3% 
oxazolone ethanol solution onto the skin of the abdomen. Five days after sensitization, 
oxazolone solution was intrarectally injected into the mice under isoflurane anesthesia 
to induce colitis. In vehicle group, ethanol/water (1:1) vehicle solution was intrarectally 
injected into the mice instead of oxazolone solution. E6130 was orally administered 1 h 
before intrarectal injection of oxazolone. The daily administration of E6130 continued 
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from Day 5 to Day 7. Two hours after the administration of E6130 on Day 7, the mice 
were euthanized by cervical dislocation, their colons were removed, and the length 
(mm) of the colons was recorded. Body weight ratio was calculated by using the 
following formula: 
Body weight ratio (%) = (Body weight at Day 7) / (Body weight at Day 5) × 100. 
 
3.2.11. Statistical analysis 
     Data are presented as means ± SEM. In stool score and relative body weight of a 
murine CD4+ CD45RBhigh T-cell transfer colitis model, differences between 
CD4+CD45RBhigh T-cell-transferred group and total-CD4+ T-cells- or E6130-treated 
group were analyzed by repeated measures analysis of variance (RM-ANOVA) 
followed by Fisher’s LSD test adjusted. In other parameters, differences between 
CD4+CD45RBhigh T-cell-transferred group and total-CD4+ T-cells- or E6130-treated 
group were analyzed by 1-way analysis of variance (ANOVA) followed by Fisher’s 
LSD test. We used Bonferroni correction for a final multiple comparison to correct for 
inflation of type 1 error, and significance level was set to 0.001 (0.05 ÷ 48). In a 
murine oxazolone-induced-colitis model, differences between oxazolone-injected group 
and vehicle (ethanol/water)-injected or E6130-treated group were analyzed by 1-way 
analysis of variance (ANOVA) followed by Fisher’s LSD test. We used Bonferroni 
correction for a final multiple comparison to correct for inflation of type 1 error, and 
significance level was set to 0.00625 (0.05 ÷ 8). Statistical analyses were performed by 
using GraphPad Prism (GraphPad Software, CA, USA). 
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3.3. Results 
3.3.1. Effect of E6130 on fractalkine-induced chemotaxis by NK cells isolated from 
human peripheral blood 
     Previously, E6130 (Fig. 3-2) was identified from a G-protein coupled receptor 
(GPCR)-focused library by using a fluorometric microvolume assay technology scanner 
designed to perform high-throughput screening assays using multiwell plates. The 
library was screened by using an in vitro chemotaxis assay and an in vivo murine 
inflammatory bowel disease model. 
     A cell-based assay was used to assess the effects of E6130 on fractalkine-induced 
chemotaxis. Human NK cells were used, because most NK cells in human peripheral 
blood express CX3CR1 on their surfaces and NK cells can be easily isolated in large 
numbers. NK cells were incubated with E6130 for 2 h and chemotaxis was induced by 
incubation with fractalkine by using a multiwell chemotaxis chamber. Marked migration 
of NK cells was observed against 0.2 nM fractalkine (number of cells in blank well: 887 
± 324, number in fractalkine-containing well: 8,615 ± 2,936). However, E6130 inhibited 
the chemotaxis of NK cells, with an IC50 value of 4.9 nM (Fig. 3-3a). 
 
3.3.2. Effect of E6130 on CX3CR1 down-regulation on the cell surface of human 
peripheral blood NK cells 
     E6130 exhibited no antagonistic activity on [35S]GTPγS binding via CX3CR1 
(Table 1). Therefore, I hypothesized that E6130 prevents fractalkine from binding to the 
receptor by inducing down-regulation of CX3CR1 on the cell surface, leading to 
inhibition of the fractalkine-induced chemotaxis of human leukocytes. To test this 
hypothesis, human peripheral blood was incubated with E6130 for 30 min at 37°C and 
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then stained with monoclonal antibodies to CD56 and CX3CR1. The fluorescence 
intensity of CX3CR1 on CD56+ NK cells was evaluated by means of flow cytometry. 
E6130 induced the down-regulation of CX3CR1 on the cell surface of CD56+ NK cells 
with an EC50 value of 5.2 nM (Fig. 3-3b). 
 
3.3.3. Effect of E6130 on GTPγS binding via CX3CR1 
     When activated, CX3CR1 changes conformation to expose a G-protein complex 
binding site. Once this G-protein complex is bound, the Gα subunit releases GDP and 
binds GTP. Agonist-activated GPCR induces receptor phosphorylation mediated by 
GPCR kinases, leading to the recruitment of -arrestin. Upon receptor phosphorylation 
and -arrestin binding, most GPCRs internalize into clathrin-coated vesicles. Therefore, 
next I examined the effects of E6130 on [35S]GTPγS binding and -arrestin recruitment 
by CX3CR1 in CX3CR1-expressing CHO-K1 membrane. E6130 had agonistic activity 
with respect to [35S]GTPγS binding (EC50 = 133 nM) and -arrestin recruitment (EC50 = 
2.4 M) through CX3CR1 (Fig. 3-4ab). No antagonistic activity of E6130 was observed 
in the presence of fractalkine (IC50 value: >10 μM). 
     The agonistic and antagonistic activities of E6130 with respect to [35S]GTPγS 
binding and -arrestin recruitment were also examined by using CHO-K1 membrane 
expressing human chemokine receptors. E6130 had agonistic activity through 
chemokine orphan receptor 1 for β-arrestin recruitment at 10 μM. However, no 
significant agonistic or antagonistic activity (EC50 and IC50 values: >10 μM) of E6130 
was observed with respect to [35S]GTPγS binding or β-arrestin recruitment through any 
other chemokine receptor (Tables 3-1, 3-2). 
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3.3.4. Effects of E6130 in a murine CD4+CD45RBhigh T-cell-transfer colitis model 
     The etiology of IBD is still not clear. In general, the major cause is dysregulation 
of immune responses induced by environmental or genetic factors. Thus, many 
genetically modified mouse models, chemical-induced models, and the T cell-transfer 
model have been established for IBD study. All these animal models indicate that the T 
cell-mediated autoimmune response plays an important role. In these IBD animal 
models, transfer of CD4+CD45RBhigh T-cell into congenic immunodeficiency mice, 
which is known as a good Crohn’s disease model, is one of the most common models. 
     The in vivo efficacy of E6130 after oral administration was assessed by using a 
murine CD4+CD45RBhigh T-cell-transfer colitis model. E6130 (10 or 30 mg/kg) was 
orally administered to the SCID mice once a day. Oral availability of E6130 was 
confirmed with pharmacokinetic study in the mice (Table 3-3). The total CD4+ T-cell 
population was used as the negative control. Stool consistency and body weight were 
recorded, and colons were excised and their weight and length were determined because 
colon length-to-weight ratio correlates well with histopathological scores [60]. The 
number of CX3CR1+ leukocytes in the lamina propria was determined by means of flow 
cytometry. Oral administration of E6130 significantly (p < 0.001) improved stool 
consistency from Day 18 at doses of 10 and 30 mg/kg compared with CD4+CD45RBhigh 
T-cell-transferred group, and significantly (p < 0.001) ameliorated body weight loss 
from Day 22 at doses of 10 and 30 mg/kg (Fig. 3-5ab). Furthermore, oral administration 
of E6130 significantly (p < 0.001) ameliorated the increased colon weight to length ratio 
as well as the increase in the number of CX3CR1+ leukocytes in the lamina propria at 
doses of 10 and 30 mg/kg (Fig. 3-6ab). These effects of E6130 were histopathologically 
confirmed by a marked reduction in mucosal thickness due to much less inflammatory 
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cell infiltration and crypt hyperplasia in treated animals (Fig. 3-7ab).  
 
3.3.5. Effects of E6130 in a murine oxazolone-induced-colitis model 
     Oxazolone-induced colitis is a T cell-driven colitis characterized by a strong 
innate granulocytic response. The in vivo efficacy of E6130 after oral administration 
was assessed in a murine oxazolone-induced-colitis model. Body weight loss and 
shrinkage of the colon are well recognized as features of hapten-induced colitis model 
[61, 62].  At a dose of 30 mg/kg, E6130 significantly (p < 0.00625) prevented the 
colon-length shortening, and significantly (p < 0.00625) suppressed the body weight loss 
on day 7 (Fig. 3-8ab). 
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3.4. Discussion 
      IBD such as Crohn’s disease and ulcerative colitis are characterized by a chronic 
clinical course of relapse and remission. In both Crohn’s disease and ulcerative colitis, 
leukocyte infiltration into the intestine is a fundamental event in the development and 
progression of the disease. Indeed, CX3CR1+CD4+ T cells are increased in the 
peripheral blood and inflamed tissues of patients with IBD. Fractalkine is expressed by 
epithelial cells in the colonic tissue and the expression is greater in the inflamed tissues 
of patients with Crohn’s disease or ulcerative colitis [56], suggesting that the 
fractalkine/CX3CR1 axis plays an important role in the pathogenesis of IBD. Therefore, 
inhibition of the trafficking of CX3CR1+ leukocytes represents a potential means of 
treating IBD. 
     I found here that E6130 had an inhibitory activity against fractalkine-induced 
chemotaxis in NK cells isolated from human peripheral blood. The down-regulation of 
CX3CR1 on the cell surface induced by E6130 mainly contribute to the inhibition of 
fractalkine-induced chemotaxis, because the down-regulation of CX3CR1-inducing 
activity of E6130 (EC50 = 5.2 nM) was more potent than its agonistic activity with 
respect to GTPS binding (EC50 = 133 nM) and -arrestin recruitment (EC50 = 2.4 M). 
E6130 exhibited no antagonistic activity on [35S]GTPγS binding via CX3CR1. I cannot 
completely ruled out the possibility that E6130 acts through a mechanism other than 
CX3CR1, because E6130 was shown to affect ACKR3/CMKOR1 in -arrestin 
recruitment at the high concentration of E6130 (10 M) (Table 3-2). In vitro data 
suggested that E6130 induced down-regulation of CX3CR1 on the cell surface, thereby 
inhibiting the interaction between fractalkine and CX3CR1, leading to inhibition of 
fractalkine-induced chemotaxis. 
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     Numerous efforts have been made to clarify the in vivo role of the 
fractalkine/CX3CR1 axis in intestinal inflammation; however, it remains unclear 
whether the fractalkine/CX3CR1 axis contributes to the progression of colitis. 
Kostadinova et al. demonstrated that knockout of CX3CR1 in mice suppressed the 
development of dextran sulfate sodium–induced colitis and inhibited the trafficking of 
inducible nitric oxide synthase–expressing macrophages into the mucosa [63]. Likewise, 
Niess and Adler demonstrated in a CD4+ T-cell adoptive-transfer colitis model that 
CX3CR1gfp/gfp/RAG2−/− mice had less colitis signs than RAG2−/− mice, fewer dendritic 
cells in the mesenteric lymph nodes, and reduced serum interferon gamma and 
interleukin 17 concentrations [64]. In contrast, Medina-Contreras et al. demonstrated 
that deletion of CX3CR1 aggravates the signs of colitis in mice [65], and Kayama et al. 
demonstrated the importance of intestinal CX3CR1high myeloid cells for the prevention 
of intestinal inflammation [66]. These inconsistent results may be due to a lack of 
expression of CX3CR1 in a specific stage during fetal development or an excessive 
compensation by other chemokine pathway or, a possibility that both too much and too 
little receptor might predispose to pathology. Therefore, to fully understand the 
mechanistic role of the fractalkine/CX3CR1 axis in intestinal inflammation, the 
fractalkine/CX3CR1 axis needs to be interrupted at the exact time at which 
inflammation begins. Here, in a murine CD4+CD45RBhigh T-cell-transfer colitis model, I 
used E6130 to interrupt the fractalkine/CX3CR1 axis during intestinal inflammation and 
found that E6130 suppressed the signs of colitis by inhibiting the infiltration of 
CX3CR1+ leukocytes into inflamed colon tissue.  
     Massive infiltration of leukocytes—including lymphocytes, macrophages, and 
neutrophils—into inflamed colonic mucosa is a hallmark of human IBD [49, 50]. In this 
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regard, chemokine/receptor axes play central roles in the trafficking of leukocytes from 
the blood into inflamed intestinal mucosa [50]. Previous studies have also shown the 
importance of the chemokine/receptor axes in the onset of T-cell-dependent, 
hapten-induced experimental colitis [67, 68]. Khan et al. reported the critical role of 
monocyte chemoattractant protein-1 (MCP-1) in a dinitrobenzenesulfonic acid-induced 
colitis model [69]. MCP-1 is a ligand for CCR2, CCR4, and CCR11, and these receptors 
are expressed by monocytes, macrophages, and certain subsets of T lymphocytes. Khan 
et al. revealed that knockout of the gene encoding MCP-1 in mice attenuates the onset 
and severity of the signs of colitis by reducing the infiltration of F4/80+ macrophages 
and CD3+ lymphocytes into inflamed mucosa [67]. Most chemokines, including MCP-1, 
can bind to several receptors, and most receptors bind many chemokines; however, 
fractalkine binds only to CX3CR1. Because the expression of MCP-1 mRNA is 
significantly decreased in CX3CR1-deficient mice compared with in wild-type mice, it 
is possible that E6130 suppresses the expression of MCP-1 in inflamed colonic tissues 
[69]. This suggests that the fractalkine/CX3CR1 axis exists upstream of other 
chemokine/receptor axes that together form a specialized system that regulates 
chemokine-induced leukocyte infiltration into the colonic mucosa. 
     In conclusion, here I characterized E6130, a novel CX3CR1 modulator. I found 
that E6130 induced down-regulation of CX3CR1 on the cell surface, leading to 
suppression of fractalkine-induced chemotaxis of CX3CR1+ human NK cells. Oral 
administration of E6130 ameliorated inflammatory bowel disease-related parameters in 
both a murine CD4+CD45RBhigh T-cell-transfer colitis model and a murine 
oxazolone-induced colitis model. In the murine CD4+CD45RBhigh T-cell-transfer colitis 
model, E6130 inhibited the trafficking of CX3CR1+ immune cells into the mucosa and 
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decreased the number of these cells in the gut mucosal membrane. Thus, E6130 is a 
potentially useful therapeutic agent for treatment of IBD such as ulcerative colitis and 
Crohn’s disease. 
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Table 3-1. Agonistic and antagonistic activities of E6130 (10 mol/L) towards 
chemokine receptors in GTPS binding 
 
a GTPS binding assay was performed for chemokine receptors. 
b Agonist activity of E6130 is expressed as a percentage of the activity of the reference 
agonists at their EC100 concentrations. Negative values indicate antagonistic activities. 
c Negative values indicate agonistic activities. 
Receptor % Activationb Receptor % Inhibitionc
CCR1 1.6 CCR1 15.1
CCR2 3.1 CCR2 24.9
CCR3 −8.1 CCR3 54.8
CCR4 −6.1 CCR4 44.0
CCR6 −5.2 CCR6 18.7
CCR7 0.9 CCR7 −15.2
CCR8 8.9 CCR8 9.7
CCR10 −5.1 CCR10 9.1
CX3CR1 95.2 CX3CR1 -18.6
CXCR1 −2.2 CXCR1 23.3
CXCR2 −3.4 CXCR2 9.1
CXCR3 2.4 CXCR3 22.7
CXCR4 0.0 CXCR4 13.2
CXCR6 −1.3 CXCR6 10.9
XCR1 −4.3 XCR1 23.8
SGTPS bindinga, Agonist mode 35SGTPS bindinga, Antagonist mode
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Table 3-2. Agonistic and antagonistic activities of E6130 (10 mol/L) towards 
chemokine receptors in -arrestin recruitment 
 
a PathHunter -arrestin assay was performed for chemokine/chemokine-like receptors. 
b Agonist activity of E6130 is expressed as a percentage of the activity of the reference 
agonists at their EC100 concentrations. Negative values indicate antagonistic activities. 
c Negative values indicate agonistic activities. 
Receptor % Activationb Receptor % Inhibitionc
CCR2 −3 CCR2 −13
CCR3 −2 CCR3 5
CCR4 −2 CCR4 −11
CCR5 −2 CCR5 0
CCR6 −2 CCR6 2
CCR7 −5 CCR7 10
CCR8 −1 CCR8 15
CCR9 −3 CCR9 6
CCR10 −1 CCR10 −15
CX3CR1 179 CX3CR1 0
CXCR1 −1 CXCR1 −10
CXCR2 −1 CXCR2 6
CXCR3 −1 CXCR3 −2
CXCR4 3 CXCR4 10
CXCR5 −2 CXCR5 4
CXCR6 1 CXCR6 −10
ACKR3/CMKOR1 157 ACKR3/CMKOR1 0
-arrestina, Agonist mode -arrestina, Antagonist mode
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Table 3-3. Plasma concentrations of E6130 after oral administration in mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
0.5 h 2 h 6 h
10 236 ± 57.3 26.4 ± 11.6 10.7 ± 5.24
30 1,430 ± 237 65.8 ± 12.6 22.8 ± 15.9
Data are shown as the mean values   S.E.M. (n = 3-6).
Dose (mg/kg)
Plasma concentration (nM)
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Fig. 3-1 Fractalkine/CX3CL1 and CX3CR1.  
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Fig. 3-2 Chemical structure of E6130. 
  
56 
 
 
 
Fig. 3-3 Effects of E6130 on fractalkine-induced chemotaxis and down-regulation of 
CX3CR1 on the cell surface in human peripheral blood natural killer cells.  
(a) Effects of E6130 on fractalkine-induced chemotaxis in human peripheral blood 
natural killer cells. Data are presented as means ± S.E.M. from three independent 
experiments performed in duplicate for the blank and control groups, and performed in a 
single well for the test compound group. (b) Effects of E6130 on the induction of 
down-regulation of CX3CR1 on the cell surface in human peripheral blood natural 
killer cells. 
Data are presented as means ± S.E.M. (n = 3). MFI, mean fluorescence intensity. 
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Fig. 3-4 Agonistic activity of E6130 against CX3CR1 with respect to GTPγS binding 
and -arrestin recruitment. 
Agonistic activity of E6130 against CX3CR1 in (a) [35S]GTPγS binding assay and (b) 
-arrestin recruitment assay. The agonistic activity of E6130 is expressed as a 
percentage of the activity of the reference agonist (fractalkine) at its EC100 
concentration. 
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Fig. 3-5 Effect of E6130 in a murine CD4+CD45RBhigh T-cell-transfer colitis model. 
(a) Stool score was assessed on the indicated days in CD4+CD45RBhigh T-cell-transfer 
mice given vehicle (solid squares), 10 mg/kg E6130 (solid circles), 30 mg/kg E6130 
(solid triangles), or total CD4+ T cells (open diamonds). (b) CD4+CD45RBhigh 
T-cell-transfer mice were administered vehicle (solid squares), 10 mg/kg E6130 (solid 
circles), or 30 mg/kg E6130 (solid triangles). Mice that received total CD4+ T cells were 
treated with vehicle (open diamonds). Body weight is expressed as the percentage of 
that at Day 14. Results are presented as means ± S.E.M. (n = 8/group). *p < 0.001 
versus vehicle in CD4+CD45RBhigh T-cell-transferred group (repeated measures analysis 
of variance (RM-ANOVA) followed by Fisher’s LSD test in each time slice).  
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Fig. 3-6 Effect of E6130 in a murine CD4+CD45RBhigh T-cell-transfer colitis model. 
(a) The colon weight to length ratio of each mouse was assessed on Day 28 after T-cell 
transfer. (b) On Day 28 after T-cell transfer, the mice were euthanized and the colons 
were excised. Leukocytes were extracted from the colon tissue by using collagenase. 
CX3CR1+ cells were labeled with phycoerythrin-conjugated anti-CX3CR1 antibody and 
the size of the CX3CR1+ cell population was determined by using a FACSCanto cell 
analyzer. Results are presented as means ± S.E.M. (n = 8/group). *p < 0.001 versus 
vehicle in CD4+CD45RBhigh T-cell-transferred group (1-way ANOVA followed by 
Fisher’s LSD test).  
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Fig. 3-8 Effect of E6130 in a murine oxazolone-induced colitis model. 
(a) Mice were euthanized, colons were excised, and colon length was measured. (b) 
Mice that intrarectally received oxazolone solution were administered vehicle (0.5% 
MC solution) (solid squares), 3 mg/kg E6130 (solid inverted triangles), 10 mg/kg E6130 
(solid circles), or 30 mg/kg E6130 (solid triangles). Mice that received same vehicle 
(ethanol/water) were treated with vehicle (0.5% MC solution) (open diamonds). Body 
weight is expressed as the percentage of that at Day 5. Data are presented as means ± 
S.E.M. (n = 9/group). *p < 0.00625 versus vehicle in oxazolone-injected group (1-way 
analysis of variance (ANOVA) followed by Fisher’s LSD test). 
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Chapter 4. Concluding Remarks 
 
     To discover better drug candidate agents for the treatment of atopic dermatitis and 
IBD, screening of Eisai’s small molecule compound libraries was conducted. E6005 and 
E6130 were identified through compound screening and chemical optimization of 
hit/lead compounds.  The aims of this investigation is to elucidate whether it is worth 
that the candidate compounds, which were identified from the screening and chemical 
optimization, introduce clinical. 
     As described in chapter 2, I first examined an inhibitory effect of E6005, a newly 
synthesized PDE4 inhibitor, on depolarization of C-fiber neuron which mediates the itch 
sensation. Results showed that E6005 suppressed C-fiber depolarization and indicates 
that this effect may lead to in vivo anti-pruritic effect. On the basis of this characteristic, 
an inhibitory effect of E6005 was investigated on oxazolone-induced scratching 
behavior in mice. Topical application of E6005 immediately inhibits itching behavior, 
suggesting that inhibitory effects of E6005 on depolarization of C-fiber neuron may (at 
least in part) contribute to the immediate anti-pruritic effect of E6005. E6005 reduces 
oxazolone-induced skin inflammation in mice. This anti-inflammatory effect of E6005 
is due to not only inhibitory effect of cytokine production such as IL-2, IL-4, IL-12, 
IFN- and TNF- but also inhibitory effect on the excitation of C-fiber neuron. Recently, 
topical application of E6005 has been shown to ameliorate skin inflammation and 
itching in Japanese adult patients with atopic dermatitis. To date, a variety of systemic 
PDE4 inhibitors have been developed. However, side effects such as particularly nausea 
and vomiting hamper their clinical utility. Emetic effect of E6005 are actually lower 
than that of cilomilast, a well-known PDE4 inhibitor, because E6005 have been 
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originally designed to lower the emetic action. Furthermore, the quite low blood 
concentration of E6005 through a topical application will enable a good systemic 
tolerability. Actually, topical application of E6005 ointment for up to 12 weeks was well 
tolerated in Japanese patients with atopic dermatitis [70, 71]. 
 In chapter 3, I assessed in vitro and in vivo pharmacological characteristics of E6130, 
a novel CX3CR1 modulator derived from Eisai’s GPCR focused libraries. In natural 
killer (NK) cells obtained from human peripheral blood, E6130 inhibited 
CX3CL1-induced chemotaxis with IC50 value of 4.9 nM. E6130 induced down 
regulation of CX3CR1 in human NK cells with EC50 value of 5.2 nM. In vitro data 
suggests that E6130 induces down regulation of CX3CR1 and thus inhibits interaction 
between CX3CL1 and CX3CR1. Such mechanism would lead to the inhibition of 
CX3CL1-induced chemotaxis. In a murine CD4+ CD45RBhigh T-cell transfer-induced 
colitis model, oral administration of E6130 decreased body weight loss and improved 
the score of stool consistency. In addition, E6130 significantly ameliorated colon 
weight/length ratio and the number of CX3CR1+ leukocytes in the lamina propria. In an 
oxazolone-induced colitis model, E6130 significantly inhibited both colon length 
shortening and body weight loss. These results suggest that E6130 is a promising novel 
therapeutic agent for the treatment of IBD. 
     As summary of this dissertation, I summarize important findings in current 
investigation as follows; i) E6005, PDE4 selective inhibitor, and E6130, CX3CR1 
modulator, were discovered from small molecule compound libraries created by Eisai, 
ii) E6005 and E6130 are promising therapeutic agents for treatment of atopic dermatitis 
and IBD, respectively, iii) clinical introduction of these compounds were achieved. 
Taken together, these finding show that developmental possibility of these compounds 
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for treatment of inflammatory diseases, and they have significant potential to offer 
innovative solution as effective therapeutics. I strongly hope that my investigation will 
lead to make drugs that fulfill the needs of patients and improve welfare of people in the 
world. 
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